CompletedPhase 2

A Study of Indinavir Plus Ritonavir Plus Two NRTIs vs. Nelfinavir Plus Two NRTIs in HIV Positive Patients (0639-112)(COMPLETED)

330 participantsStarted 2001-01

Plain-language summary

A study comparing Indinavir plus Ritonavir plus 2 NRTIs vs. Nelfinavir 1250 plus two nucleoside reverse transcriptase inhibitors (NRTIs) in the treatment of HIV positive patients who have not responded to or are intolerant to a non-nucleoside reverse transcriptase inhibitor (NNRTI) containing treatment.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * At least 18 years of age * HIV positive * No active heart disease Exclusion Criteria: * Pregnant or breast feeding * Unwilling to use birth control or abstinence to prevent pregnancy * Received an investigational drug or vaccine within the past 30 days or is planning to receive other investigational study drug/vaccine or interferon while in the study * Plan to receive NNRTIs while in the study * Received therapy which lowers body's ability to fight infection within the past 30 days or while in the study * Alcohol or substance abuse * Hepatitis

What they're measuring

Plasma viral RNA levels will be measured at predetermined time points to determine mean change

Trial details

NCT IDNCT00541463

SponsorMerck Sharp & Dohme LLC

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

View on ClinicalTrials.gov More HIV Infections trials